Podcast Episodes
Back to Search
Ep. 376 - M&A momentum: 3Q public markets preview
Season 7 Episode 376
M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCe…
1 month, 3 weeks ago
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Season 7 Episode 375
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode…
2 months ago
Ep. 374 - Parkinson's deep dive & FDA trial reforms
Season 7 Episode 374
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapie…
2 months, 1 week ago
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Season 7 Episode 373
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the lates…
2 months, 2 weeks ago
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Season 7 Episode 372
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analyst…
2 months, 3 weeks ago
Ep. 371 - Moving faster at the academia-industry interface
Season 7 Episode 371
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.
From AI to NAM…
2 months, 4 weeks ago
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Season 7 Episode 370
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the lates…
3 months ago
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Season 7 Episode 369
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCen…
3 months, 1 week ago
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Season 7 Episode 368
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bi…
3 months, 1 week ago
Ep. 367 - FDA, obesity targets and the rise of DACs
Season 7 Episode 367
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioC…
3 months, 3 weeks ago